38,411 Shares in AstraZeneca PLC $AZN Bought by My Personal CFO LLC

My Personal CFO LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 38,411 shares of the company’s stock, valued at approximately $2,947,000. AstraZeneca makes up 1.1% of My Personal CFO LLC’s holdings, making the stock its 25th largest holding.

A number of other institutional investors have also added to or reduced their stakes in the business. Chapin Davis Inc. raised its holdings in shares of AstraZeneca by 3.3% in the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after acquiring an additional 120 shares in the last quarter. Highline Wealth Partners LLC increased its position in shares of AstraZeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after purchasing an additional 129 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in AstraZeneca by 0.6% in the third quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock valued at $1,628,000 after purchasing an additional 136 shares in the last quarter. Pekin Hardy Strauss Inc. lifted its position in AstraZeneca by 4.2% during the second quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock valued at $255,000 after purchasing an additional 148 shares during the last quarter. Finally, Richardson Financial Services Inc. grew its stake in AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Down 0.6%

Shares of NASDAQ:AZN opened at $91.93 on Thursday. The stock’s 50-day moving average price is $88.87 and its 200-day moving average price is $80.88. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $94.01. The stock has a market capitalization of $285.12 billion, a P/E ratio of 30.54, a price-to-earnings-growth ratio of 1.72 and a beta of 0.32. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter in the previous year, the company posted $2.08 EPS. AstraZeneca’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on AZN shares. HSBC restated a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 10th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Cowen reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.